Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
James M Dubois · WASHINGTON UNIVERSITY · 2022 · $561,127 — Project Summary Religion is a primary driver of concerns with genomics and genomic healthcare (GGH). It is vital for research on the ethical, legal, and social implications (ELSI) of genomics to understand the role of religion in shaping public attitudes toward GGH. Ninety percent of the US public …
Elias Sayour · UNIVERSITY OF FLORIDA · 2022 · $476,622 — Project Summary While activated T cells cross the blood-brain barrier (BBB), immunotherapy has yet to be harnessed for targeted therapy due to GBM’s heterogeneity and immunosuppressive microenvironment. Unleashing immunotherapy against GBM requires new technologies that activate the tumor microenvir…
Paul Stephen Keim · NORTHERN ARIZONA UNIVERSITY · 2022 · $1,519,099 — OVERALL Section Title: Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis. SUMMARY Coccidioidomycosis, also known as Valley Fever (VF), is an important fungal disease caused by two different Coccidioides species that results in regional…
John Daniel Kelly · VETERANS AFFAIRS MED CTR SAN FRANCISCO · 2022 — As SARS-CoV-2 vaccines enter mass distribution, little is known about vaccinated individuals who nonetheless develop Covid-19 (symptomatic disease or “vaccine failure”), require hospitalization, and die. Pfizer-BioNTech reported 3.8 vaccine failure cases/1,000 person-years, meaning vaccine failure w…
qing sun · TEXAS ENGINEERING EXPERIMENT STATION · 2022 · $361,174 — Among all approaches, messenger RNA (mRNA)-based vaccines have emerged as a rapid and versatile candidate to quickly respond to virus pandemics, including coronavirus disease 2019 (COVID-19). But mRNA vaccines face key potential limitations. Researchers have observed that RNA molecules tend to spont…
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2022 · $368,909 — PROJECT SUMMARY/ABSTRACT High-risk human papillomaviruses (HR HPVs) cause 5% of all cancers. There are preventive vaccines against HPV, but less than 2% of the world's target population has received them. This leaves millions of women and men at risk for HPV-associated cervical, anogenital, and hea…
Yuan Shi · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $390,000 — Project Summary Influenza A virus causes disease in 5-20% of the population with over 200,000 hospitalizations annually in US. The antigen drift and shift of influenza virus pose a serious challenge for flu vaccination program. Although IFN response is known as the first important host defending mec…
Henry Charles Mwandumba · CORNELL UNIVERSITY · 2022 · $658,518 — Our recent advances in the use of fluorescent fitness reporter Mtb strains in the murine TB model has afforded us a unique appreciation of the role of macrophage lineages in both the control and promotion of Mtb growth. Moreover, the extension of these observations through the successful development…
Michael Gerner · UNIVERSITY OF WASHINGTON · 2022 · $441,250 — The innate and adaptive arms of the immune system are integrally linked, with dendritic cells (DCs), innate antigen presenting cells, providing critical instructions to elicit the generation of adaptive T cell immunity. Using a novel analytical imaging approach, we recently uncovered that different …
THOMAS MELENDY · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2022 · $239,250 — Project Summary/Abstract: Effective antivirals are sorely needed against SARS CoV-2 (CoV2), and coronaviruses (CoV) in general. Screening systems for drugs targeting CoV2 enzymes usually involve screening against purified enzymes. This can be technically challenging, and the vast majority of inhibit…
RONALD LEVY · STANFORD UNIVERSITY · 2022 · $512,443 — Project Summary: Cancer is a leading global cause of mortality. The goal of this multi-disciplinary project is to pre-clinically advance a novel concept for selective and efficient mRNA delivery that enables a highly promising vaccination strategy for cancer immunotherapy. Given the potential of can…
YASUHIRO SUZUKI · UNIVERSITY OF KENTUCKY · 2022 · $459,000 — Chronic infection with Toxoplasma gondii can reactivate and cause life-threatening toxoplasmic encephalitis in AIDS patients and other immunocompromised individuals. The basis of persistence of this chronic infection is the tissue cyst. Thus, eliminating T. gondii cysts from chronically infected ind…
Emily K. Moser · UNIVERSITY OF FLORIDA · 2022 · $108,000 — PROJECT SUMMARY/ABSTRACT The NIH estimates that up to 23.5 million Americans suffer from autoimmune disease, driven in large part by germinal center (GC)-derived pathologic autoantibodies. GC B cells undergo iterative rounds of somatic hypermutation of B cell receptor (BCR) genes, and selection bas…
John H Adams · UNIVERSITY OF SOUTH FLORIDA · 2022 · $975,965 — Project Summary/Abstract Plasmodium vivax is the second leading cause of malaria and the most prevalent cause of malaria outside of Africa. The estimated cost of the global burden of vivax malaria is $1.4 - $4 billion per year and more people live at risk worldwide from P. vivax than P. falciparum. …
Peter Shen · NORTHWESTERN UNIVERSITY AT CHICAGO · 2022 · $482,787 — PROJECT SUMMARY Poxviruses include family members that are categorized as Class A Priority Pathogens with significant future pandemic potential, while modified forms of other family members are widely used as vaccine vectors and oncolytic therapeutics. Beyond their more direct medical significance, …
Elias Sayour · UNIVERSITY OF FLORIDA · 2022 · $1,262,498 — Project Summary: Despite standard of care with maximal surgical resection, external beam radiotherapy, and chemotherapy, patients with glioblastoma (GBM) live little more than 18 months after diagnosis; these outcomes necessitate development of new targeted therapies. To address this gap, our group …
Edward M. Schwarz · UNIVERSITY OF ROCHESTER · 2022 · $1,402,705 — Abstract Bone infection caused by Staphylococcus aureus remains the bane of orthopaedic surgery, as diagnostics, prophylactics and treatments have significant shortcomings that result in catastrophic outcomes for patients, and crippling healthcare costs. Although the incidence of infection following…
SAAD BHAMLA · GEORGIA INSTITUTE OF TECHNOLOGY · 2022 · $270,000 — Project Summary/Abstract Given modern history’s advancements in molecular biology, from the exponential decrease in the costs of genome sequencing, nucleotide synthesis, and genome editing (CRISPR), synthetic biology is poised to be the next major revolution in technological advancements. The White …
Scott Eric Hensley · UNIVERSITY OF PENNSYLVANIA · 2022 · $398,577 — Modified Project Summary/Abstract Section Most humans are infected with influenza viruses by the time they reach 3 years of age. Our past studies suggest that early childhood influenza infections can leave lifelong immunological ‘imprints’. During the first funding period (4 years) of this grant,…
John Tsang · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $230,985 — We have been integrating computational approaches and cutting-edge high-throughput methods to assess changes in the epigenome, transcriptome, and proteome throughout the course of COVID-19 disease. We also have been applying similar approaches to study the responses of the COVID-19 mRNA vaccines in …